MA
PFE icon

Maxele Advisors’s Pfizer PFE Stock Holding History

Maxele Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,714
Closed -$205K – 100
2024
Q4 		$205K Buy
+7,714
New +$209K 0.2% 97
2022
Q3 		$373K Sell
8,535
-19
-0.2% -$923 0.63% 46
2022
Q2 		$448K Hold
8,554
– – 0.7% 44
2022
Q1 		$443K Hold
8,554
– – 0.55% 47
2021
Q4 		$505K Buy
+8,554
New +$424K 0.58% 47

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Maxele Advisors's PFE Position: Q1 2025 in Review

Maxele Advisors sold out of Pfizer (PFE) in Q1 2025, closing a stake of 7,714 shares — an estimated $205K sold.

Maxele Advisors first reported a position in PFE in Q4 2021 and held it in 5 quarters. The position peaked at $505K in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • Maxele Advisors reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
  • Maxele Advisors sold 7,714 Pfizer shares in Q1 2025, an estimated $205K.
  • Maxele Advisors first reported a position in Pfizer in Q4 2021 and held it in 5 quarters.
  • Maxele Advisors's Pfizer position peaked at $505K in Q4 2021.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Maxele Advisors's 13F filing for Q1 2025, filed 1 Dec 2025.